

## RECEIVED

SEP 0 4 2003

TECH CENTER 1600/2900 (PATENT)

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Mark G. ERLANDER, et al.

Application No.: 10/028,018

Filed: December 21, 2001

For: BREAST CANCER PROGRESSION

SIGNATURES

Group Art Unit: 1645

Examiner: Not Yet Assigned

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 CFR 1.97, Applicant(s) hereby make of record the following additional documents. A Form PTO-1449 and a full copy of each of these documents accompany this statement.

Applicant(s) have become aware of the following documents, cited in an International Search Report issued June 19, 2003, during the prosecution of international application no. PCT/US02/41216, which corresponds to the above referenced application, and in accordance with 37 CFR 1.97(c) and (e)(1) or (b)(3), hereby submit(s) these documents for the Examiner's consideration. These documents are cited on the enclosed Form PTO-1449, and a copy of the International Search Report and each document cited thereon are enclosed as well.

Application No.: 10/028,018 2 Docket No.: 485772004300

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicant(s) understand(s) the Examiner will make an independent evaluation of the cited documents.

The undersigned hereby certifies that each item contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Dated: August 22, 2003

Respectfully submitted,

Kawai Lau

Registration No.: 44,461 MORRISON & FOERSTER LLP 3811 Valley Centre, Suite 500

San Diego, California 92130 Telephone: (858) 720-5178 Facsimile: (858) 720-5125

Attorneys for Applicant

PTO/SB/08 (2-92)

Sheet 1 of 1

## Form PTO-1449

#### INFORMATION DISCLOSURE **CITATION** IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 485772004300	Application Number 10/028,018

Applicant

Mark G. ERLANDER et al.

Filing Date December 21, 2001

Mailing Date August 28, 2003

Group Art Unit 1645

SEP & 4 2003

1. H CENTER 1600/2900

## **U.S. PATENT DOCUMENTS**

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.		2002/0102265	Hong et al.			07/02/2001
	2.		2002/0044941	Rosen et al.			08/10/2001
	3.		2003/0087270	Schlegel et al.			06/12/2002

### FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	4.	Affymetrix Product Brochure. Gene Chip Human Genome U133 Set. (2001). pp.1-7.
	5.	Gruvberger, S. et al. "Estrogen Receptor Status in Breast Cancer Is Associated with Remarkable Distinct Gene Expression Patterns." Cancer Research (2001). 61(16):5979-5984.
	6.	Sengar, A.S. et al. "The EH and SHE3 domain Ese proteins regulate endocytosis by linking to dynamin and EPS15." The EMBO Journal (1999) 18(5):1159-1171.
	7.	Thomas, R.S. et al. "The Elf Group of ETS-Related Transcription Factors ELF3 and ELF5." Advances in Experimental Medicine and Biology. (2000) 480:123-128.
	8.	Zhou, J. et. al. "A Novel Transcription Factor, ELF5, belongs to the ELF subfamily of ETS genes and Maps to Human Chromosome 11p13-15, a Region Subject to LOH and Rearrangment in Human Carcinoma Cell Lines." Oncogene. (1998). 17:2719-2732.

**EXAMINER:** 

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/21 (05-03) Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control nun

**Examiner Name** 

# TRANSMITTAL **FORM**

(to be used for all correspondence after initial filing)

**Application Number** 10/028,018 RECEIVED December 21, 2001 Filing Date First Named Inventor Mark G. ERLANDER SEP 0 4 2003 Art Unit 1645

Not Yet Assigned

TECH CENTER 1600/2900 12 + 8485772004300 Total Number of Pages in This Submission Attorney Docket Number REFERENCES ENCLOSURES (check all that apply) Drawing(s) After Allowance Communication Fee Transmittal Form to Group Appeal Communication to Board of Fee Attached Licensing-related Papers Appeals and Interferences Appeal Communication to Group Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Provisional **Proprietary Information** After Final Application Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) (please Terminal Disclaimer Extension of Time Request identify below): Copy of International Search Request for Refund **Express Abandonment Request** Report (7 pages) Form PTO-1449 (1 page, plus Information Disclosure Statement CD, Number of CD(s) duplicate) (2 pages) References (8) Return Receipt Postcard Certified Copy of Priority Document(s) Remarks Response to Missing Parts/ Incomplete Application Customer No. 25225 Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm MORRISON & FOERSTER LLP Kawai Lau - 44,461 Individual name Signature Date 

I hereby certify that this corres	pondence is being deposited wit	h the U.S. Postal Service with sufficient po	stage as First Class Mail, in
an envelope addressed to: Co	ommissioner for Patents, P.O. Bo	ox 1450, Alexandria, VA 22313-1450, on the	ne date shown below.
Dated: August <u>38</u> , 2003	Signature:	(Diane Blevins)	